Compare UiPath Inc (PATH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs TransMedics Group Inc — how do they compare? UiPath Inc trades at $13.25 (market cap $6.81B), while TransMedics Group Inc trades at $79.01 (market cap $2.81B). The key difference: UiPath Inc is far larger — about 2.4× TransMedics Group Inc's market cap, and UiPath Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and TransMedics Group Inc for 24 Days on average.
| PATH | TMDX | |
|---|---|---|
Market Cap | $6.81B | $2.81B |
Volume | 22,766,109 | 962,415 |
Sector | Technology | Health |
52-Week High | $19.29 | $150.42 |
52-Week Low | $9.38 | $61.99 |
Typical Hold Time | 139 Days | 24 Days |
Enterprise Value | $5.61B | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
